Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
GlaxoSmithKline (GSK) and Eli Lilly are making major U.S. manufacturing commitments as global pharmaceutical companies expand domestic operations in response to possible tariffs on imported medicines. According to The Wall Street Journal, more than a dozen drugmakers have pledged over $350 billion in U.S. investments this decade to strengthen local supply chains and reduce tariff risks.
GSK (LON:GSK) revealed plans to spend $30 billion in the United States over the next five years, focusing on research, supply-chain infrastructure, and new production facilities. The investment includes $1.2 billion for a new factory near Philadelphia dedicated to developing treatments for respiratory illnesses and cancer. The move positions GSK to boost U.S. drug production while creating new jobs in the biopharma sector.
Meanwhile, Eli Lilly (NYSE:LLY) announced a $5 billion investment to build a state-of-the-art plant near Richmond, Virginia. The facility will specialize in manufacturing monoclonal antibodies and bioconjugates, critical therapies in oncology and immunology. Once operational, the plant is expected to employ approximately 650 workers, enhancing Lilly’s domestic manufacturing footprint and supporting innovation in biologic medicines.
The surge in U.S. pharmaceutical investments comes as the Trump administration considers imposing tariffs on imported drugs, with rates potentially climbing to 250% within 18 months. Such measures could significantly impact global supply chains, pushing companies to accelerate onshore production strategies.
By committing billions to U.S. manufacturing, GSK and Eli Lilly join a broader trend of pharmaceutical giants prioritizing local capacity. These investments are expected to safeguard supply resilience, stimulate job creation, and position drugmakers to better navigate policy changes affecting the global pharmaceutical market.
